Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
Reissue PAR-21-122. Offered by National Institutes of Health; applications due October 20, 2027.
Key Facts
- Funder
- National Institutes of Health
- Award amount
- Not specified by funder
- Deadline
- October 20, 2027
- Geography
- United States
- Categories
- Research
- Status
- Open
About This Grant
Reissue PAR-21-122. This NOFO provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders that fall under the NINDS mission. Therapeutic agents include small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational...
Full requirements and application instructions: official listing.
Similar Open Grants
Research Centers in Minority Institutions (RCMI) Coordinating Center (U24 - Clinical Trial Optional)
National Institutes of Health
Single Source: Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States (U19 - Clinical Trial Not Allowed)
National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
National Institutes of Health
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
National Institutes of Health
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
National Institutes of Health
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
National Institutes of Health
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)
National Institutes of Health
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)
National Institutes of Health
Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
National Institutes of Health
Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
National Institutes of Health